GCNT2 and metastatic melanoma: Staining a panel of clinical specimens, including normal skin, benign nevi, and primary and metastatic melanomas, revealed that GCNT2 is downregulated as melanomas progress from a normal to a malignant and metastatic state (Fig. 3a–e and Supplementary Fig. 3b, c).